tiprankstipranks
Trending News
More News >
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market

Theravance Biopharma (TBPH) Financial Statements

Compare
349 Followers

Theravance Biopharma Financial Overview

Theravance Biopharma's market cap is currently $956.70M. The company's EPS TTM is $0.07; its P/E ratio is 33.81; Theravance Biopharma is scheduled to report earnings on November 10, 2025, and the estimated EPS forecast is $1.00. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 64.38M$ 57.42M$ 51.35M$ 55.31M$ 71.86M
Gross Profit$ 64.38M$ 16.80M$ -12.05M$ -138.35M$ 71.86M
Operating Income$ -46.95M$ -56.03M$ -91.96M$ -257.78M$ -297.63M
EBITDA$ -38.45M$ -51.65M$ -76.08M$ -232.83M$ -287.82M
Net Income$ -56.42M$ -55.19M$ 872.13M$ -199.43M$ -278.02M
Balance Sheet
Cash & Short-Term Investments$ 88.35M$ 102.43M$ 327.48M$ 173.47M$ 292.94M
Total Assets$ 354.16M$ 382.00M$ 607.40M$ 374.82M$ 469.06M
Total Debt$ 49.82M$ 49.16M$ 52.16M$ 669.52M$ 676.26M
Net Debt$ 12.02M$ 9.61M$ -246.01M$ 579.56M$ 594.79M
Total Liabilities$ 178.62M$ 169.00M$ 165.60M$ 713.39M$ 772.81M
Stockholders' Equity$ 175.54M$ 213.00M$ 441.80M$ -338.57M$ -303.75M
Cash Flow
Free Cash Flow$ -11.87M$ -29.48M$ -187.56M$ -211.26M$ -257.02M
Operating Cash Flow$ -11.54M$ -27.00M$ -186.99M$ -207.86M$ -250.40M
Investing Cash Flow$ 12.28M$ -32.70M$ 1.15B$ 124.49M$ 10.72M
Financing Cash Flow$ -2.50M$ -198.93M$ -758.81M$ 91.86M$ 263.08M
Currency in USD

Theravance Biopharma Earnings and Revenue History

Theravance Biopharma Debt to Assets

Theravance Biopharma Cash Flow

Theravance Biopharma Forecast EPS vs Actual EPS